52 related articles for article (PubMed ID: 38575149)
1. Effectiveness of COVID-19 XBB.1.5 monovalent mRNA vaccine in Korea: interim analysis.
Nham E; Sohn JW; Choi WS; Wie SH; Lee J; Lee JS; Jeong HW; Eom JS; Choi YJ; Seong H; Yoon JG; Noh JY; Song JY; Cheong HJ; Kim WJ
Front Immunol; 2024; 15():1382944. PubMed ID: 38803497
[TBL] [Abstract][Full Text] [Related]
2. Humoral response superiority of the monovalent XBB.1.5 over the bivalent BA.1 and BA.5 mRNA COVID-19 vaccines.
Lustig Y; Barda N; Weiss-Ottolenghi Y; Indenbaum V; Margalit I; Asraf K; Doolman R; Chalkias S; Das R; Elfatarany G; Harats D; Kreiss Y; Regev-Yochay G
Vaccine; 2024 May; ():. PubMed ID: 38806352
[TBL] [Abstract][Full Text] [Related]
3. Immunogenicity of a 2-Dose Regimen of Moderna mRNA Beta/Omicron BA.1 Bivalent Variant Vaccine Boost in a Randomized Clinical Trial.
Rouphael NG; Branche AR; Diemert DJ; Falsey AR; Losada C; Baden LR; Frey SE; Whitaker JA; Little SJ; Kamidani S; Walter EB; Novak RM; Rupp R; Jackson LA; Babu TM; Kottkamp AC; Luetkemeyer AF; Immergluck LC; Presti RM; Bäcker M; Winokur PL; Mahgoub SM; Goepfert PA; Fusco DN; Atmar RL; Posavad CM; Netzl A; Smith DJ; Telu K; Mu J; McQuarrie LJ; Makowski M; Makhene MK; Crandon S; Montefiori DC; Roberts PC; Beigel JH;
J Infect Dis; 2023 Dec; 228(12):1662-1666. PubMed ID: 37561027
[TBL] [Abstract][Full Text] [Related]
4. Emergence and dissemination of SARS-CoV-2 XBB.1.5 in New York.
Gámbaro F; Duerr R; Dimartino D; Marier C; Iturrate E; Mulligan MJ; Heguy A; Dellicour S
Virus Evol; 2024; 10(1):veae035. PubMed ID: 38774310
[TBL] [Abstract][Full Text] [Related]
5. Humoral Immunity Elicited by the XBB.1.5 Monovalent COVID-19 Vaccine.
Nguyenla XH; Bates TA; Trank-Greene M; Wahedi M; Tafesse FG; Curlin M
medRxiv; 2024 Mar; ():. PubMed ID: 38585892
[TBL] [Abstract][Full Text] [Related]
6. Immunogenicity of a Two Dose Regimen of Moderna mRNA Beta/Omicron BA.1 Bivalent Variant Vaccine Boost in a Randomized Clinical Trial.
Rouphael NG; Branche AR; Diemert DJ; Falsey AR; Losada C; Baden LR; Frey SE; Whitaker JA; Little SJ; Kamidani S; Walter EB; Novak RM; Rupp R; Jackson LA; Babu TM; Kottkamp AC; Luetkemeyer AF; Immergluck LC; Presti RM; Bäcker M; Winokur PL; Mahgoub SM; Goepfert PA; Fusco DN; Atmar RL; Posavad CM; Netzl A; Smith DJ; Telu K; Mu J; Makowski M; Makhene MK; Crandon S; Montefiori DC; Roberts PC; Beigel JH
medRxiv; 2023 Jun; ():. PubMed ID: 37333252
[TBL] [Abstract][Full Text] [Related]
7. Real-world evidence on the efficacy of bivalent booster doses of SARS-CoV-2 vaccine in respect of monovalent boosters or primary cycle of vaccination: a narrative review.
Sane Schepisi M
Epidemiol Prev; 2023; 47(6):331-343. PubMed ID: 38314543
[TBL] [Abstract][Full Text] [Related]
8. A systematic review and meta-analysis on the effectiveness of bivalent mRNA booster vaccines against Omicron variants.
Song S; Madewell ZJ; Liu M; Miao Y; Xiang S; Huo Y; Sarkar S; Chowdhury A; Longini IM; Yang Y
Vaccine; 2024 May; 42(15):3389-3396. PubMed ID: 38653679
[TBL] [Abstract][Full Text] [Related]
9. Effectiveness and durability of mRNA-1273 BA.4/BA.5 bivalent vaccine (mRNA-1273.222) against SARS-CoV-2 BA.4/BA.5 and XBB sublineages.
Ackerson BK; Bruxvoort KJ; Qian L; Sy LS; Qiu S; Tubert JE; Lee GS; Ku JH; Florea A; Luo Y; Bathala R; Stern J; Choi SK; Takhar HS; Aragones M; Marks MA; Anderson EJ; Zhou CK; Sun T; Talarico CA; Tseng HF
Hum Vaccin Immunother; 2024 Dec; 20(1):2335052. PubMed ID: 38575149
[TBL] [Abstract][Full Text] [Related]
10. Effectiveness of BNT162b2 BA.4/5 bivalent mRNA vaccine against a range of COVID-19 outcomes in a large health system in the USA: a test-negative case-control study.
Tartof SY; Slezak JM; Puzniak L; Hong V; Frankland TB; Ackerson BK; Xie F; Takhar H; Ogun OA; Simmons S; Zamparo JM; Valluri SR; Jodar L; McLaughlin JM
Lancet Respir Med; 2023 Dec; 11(12):1089-1100. PubMed ID: 37898148
[TBL] [Abstract][Full Text] [Related]
11. Early Estimates of Bivalent mRNA Booster Dose Vaccine Effectiveness in Preventing Symptomatic SARS-CoV-2 Infection Attributable to Omicron BA.5- and XBB/XBB.1.5-Related Sublineages Among Immunocompetent Adults - Increasing Community Access to Testing Program, United States, December 2022-January 2023.
Link-Gelles R; Ciesla AA; Roper LE; Scobie HM; Ali AR; Miller JD; Wiegand RE; Accorsi EK; Verani JR; Shang N; Derado G; Britton A; Smith ZR; Fleming-Dutra KE
MMWR Morb Mortal Wkly Rep; 2023 Feb; 72(5):119-124. PubMed ID: 36730051
[TBL] [Abstract][Full Text] [Related]
12. Relative effectiveness of monovalent and bivalent mRNA boosters in preventing severe COVID-19 due to omicron BA.5 infection up to 4 months post-administration in people aged 60 years or older in Italy: a retrospective matched cohort study.
Mateo-Urdiales A; Sacco C; Fotakis EA; Del Manso M; Bella A; Riccardo F; Bressi M; Rota MC; Petrone D; Siddu A; Fedele G; Stefanelli P; Palamara AT; Brusaferro S; Rezza G; Pezzotti P; Fabiani M
Lancet Infect Dis; 2023 Dec; 23(12):1349-1359. PubMed ID: 37478877
[TBL] [Abstract][Full Text] [Related]
13. Relative effectiveness of bivalent Original/Omicron BA.4-5 mRNA vaccine in preventing severe COVID-19 in persons 60 years and above during SARS-CoV-2 Omicron XBB.1.5 and other XBB sublineages circulation, Italy, April to June 2023.
Fabiani M; Mateo-Urdiales A; Sacco C; Rota MC; Fotakis EA; Petrone D; Del Manso M; Siddu A; Stefanelli P; Bella A; Riccardo F; Rezza G; Palamara AT; Brusaferro S; Pezzotti P;
Euro Surveill; 2023 Aug; 28(32):. PubMed ID: 37561053
[TBL] [Abstract][Full Text] [Related]
14. BNT162b2 vaccine protection against omicron and effect of previous infection variant and vaccination sequence among children and adolescents in Singapore: a population-based cohort study.
Yung CF; Pang D; Kam KQ; Lye DC; Ong B; Chong CY; Tan KB
Lancet Child Adolesc Health; 2023 Jul; 7(7):463-470. PubMed ID: 37201540
[TBL] [Abstract][Full Text] [Related]
15. Factors associated with uptake of bivalent mRNA COVID-19 vaccines in a large US health care system.
Bruxvoort KJ; Sy LS; Hong V; Lewin B; Qian L; Huang X; Holmquist KJ; Han B; Xu S
Vaccine; 2023 Nov; 41(49):7460-7468. PubMed ID: 37953096
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
